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Life is inherently risky. Some individuals manage to
avoid the consequences of these risks over many years,
whereas others are not so fortunate. The lifetime risk of
dying, of course, is 100%. However, the magnitude of
the risk for acquiring a diagnosis of a speciﬁc disease or
groupofdiseases overa lifetime (also called cumulative
incidence of diseases) varies widely according to the
frequency of the disease in the population as a whole,
how the occurrence of the disease is spread over the
lifetime of individuals, and how the disease is deﬁned
and ascertained. For example, the lifetime risk of
developing cancer is 1 in 2; however, the lifetime risk
for colon cancer speciﬁcally is 1 in 21.Diseases are often
deﬁned as a departure from a reference population of
normal, healthy persons; however,making such a clear
separation between disease and normality is often a
difﬁcult task (1). This is especially true in the case of
identifying generic CKD, because clinical manifesta-
tions often occur late and frequently not even until
RRT is needed (2,3). Thus, nephrologists have come
to rely heavily on biomarkers, mainly eGFR and albu-
minuria (or proteinuria), for deﬁnition of generic CKD
(2). Although measured GFR (mGFR; by inulin, io-
hexol, or iothalamate clearances) is the preferred
method of assessing GFR when a high degree of pre-
cision is required in a given individual or in clinical
trials, an eGFR using an equation based on serum cre-
atinine or serum cystatin C concentrations or their
combination is sufﬁcient for many clinical and nearly
all epidemiologic purposes (4,5). Albuminuria (or pro-
teinuria) can be determined by qualitative or quantita-
tive tests on untimed or timedurine samples. Applying
the results of these biomarker assessments for diagnos-
ing CKD and thus determining risk over time is a
daunting task with numerous challenges.
The issue of diagnosing CKD is central to understand-
ing results of a study of lifetime risk of developing
stage 3–5 CKD in a well characterized Icelandic popula-
tion of men and women reported by Inker et al. in this
issue of CJASN (6). The authors prospectively followed
for 25 years (from 1967 to 2005) 3888 people in Iceland.
At baseline, the mean age was 4767 years, both gen-
ders were equally represented, and all participants
had an eGFR (calculated by the Chronic Kidney Disease
Epidemiology Collaboration equation).60 ml/min per
1.73 m2. Such a long follow-up in a large sample of
patients is quite unique in the nephrologic literature.
The goal of the authors was to assess the lifetime risk
(cumulative incidence) of generic CKD deﬁned as (1)
an eGFR of ,60 ml/min per 1.73 m2 on two consecu-
tive measurements [equal to that utilized by the Kidney
Disease Improving Global Outcomes clinical practice
guidelines (2)], (2) kidney failure treated by dialysis
or transplantation, (3) one measurement of eGFR,45
ml/min per 1.73 m2 if it was the last measurement, or
(4) onemeasurement of eGFR,60ml/min per 1.73m2
if the patient died before the next measurement. Albu-
minuria (or proteinuria) was not assessed. Obviously, the
lifetime risk of generic CKD was very dependent on the
deﬁnition used for CKD. For example, the risk of CKD
at 20 years for a 45-year-old woman was 8.6% if CKD
was deﬁned by two consecutive measurements
of eGFR,60 ml/min per 1.73 m2 or 16.8% if CKD
was deﬁned by only one measurement of eGFR
,60 ml/min per 1.73 m2 (6). Because chronicity
implies a notion of time by its nature, the ﬁrst CKD
deﬁnition (with a second conﬁrmatory result) seems
more relevant (2). In addition, the speciﬁc threshold
of eGFR used in this analysis for separating CKD
from non-CKD is arbitrary and absolute, rather than
stratiﬁed by age.
These results need tobe contrastedwithother studies
that examined lifetime risk of CKD, including retro-
spective, simulation models in which CKDwas deﬁned
by only one value of eGFR (7,8). In their longitudinal
analysis, Inker et al. clearly demonstrated that eGFR
decreased progressively with aging; unsurprisingly,
the diagnosis of CKD, using a single threshold, in-
creased with aging (6). Unfortunately, the absence of
data on eGFR slopes with aging makes it difﬁcult to
compare this study with other longitudinal studies
on the decline of GFR with aging (9,10). In the context
of the well established GFR decline with healthy aging,
the reference base of normality is also very important.
Cross-sectional datawith eGFRandmGFRhave clearly
shown that otherwise healthy people demonstrate a
decline in GFR to values ,60 ml/min per 1.73 m2 with
aging, especially in women aged .65 years (3,11–14).
Thus, it is not surprising that using the deﬁnitions of
Inker et al., the lifetime risk (to age 85 years) of CKD is
greater in women than in men; this is the opposite of
what is seen from calculations of lifetime risk of treated
ESRD, inwhichmen have a greater (about 1.5-fold) risk
than women (15). Although many alternative schemas
for deﬁning CKD based on eGFR are possible, one that
alters the threshold based on age is both plausible and
desirable (16). For example, we have proposed that an
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should become the new eGFR threshold for deﬁnition of
CKD in people aged .65 years without any albuminuria
or other signs of kidney damage (16). A change in the criteria
for deﬁning CKD would have a substantial effect on the cu-
mulative incidence of CKD in the population at large. In-
deed, applying an age-stratiﬁed eGFR threshold to the data
of Inker et al. (Table 4 in their study), one ﬁnds that the life-
time risk of reaching stage 3 CKD after 20 years of follow-up
of a 55-year-old person decreases from 15.2% to 3.1% in men
and from 30.4% to 4.4% in women (6). Because albuminuria
results are not available in this analysis, the true CKD prev-
alence cannot be calculated; however, we know that the vast
majority of CKD in people aged.65 years is diagnosed only
according to the eGFR threshold criteria (17).
The data of Inker et al. are purely descriptive and thus
cannot speciﬁcally address the long-lasting but still unre-
solved debate between opponents and defenders of an
“age-calibrated” eGFR or other alternative schemas for def-
inition of generic CKD (16,18). However, the observed as-
sociation between decreased eGFR (i.e., ,60 ml/min per
1.73 m2) and mortality (all-cause or cardiovascular) is an
important justiﬁcation for the choice of the GFR threshold
for CKD deﬁnition. One study showed that association be-
tween eGFR andmortality or ESRD,60ml/min per 1.73m2
was similar in young and elderly people (19). However, the
calculation of hazard ratios is subject to several alternative
interpretations (20). In addition, data from a large Canadian
database conﬁrmed that life expectancy was similar in el-
derly persons if stage 3A CKD or stage 1–2 CKD were com-
pared (21). In a very recent study from Sweden, eGFR was
followed in elderlywomen for 10 years between ages 75 and
85 years. This study also found that stage 3B CKD, but not
stage 3A, was associated with mortality in 1011 women
considered at baseline; however, large conﬁdence intervals
and a potential lack of statistical power do not fully exclude
a clinically important higher risk even in stage 3A (22).
Itmustalsobeemphasizedthatnoevidencecurrentlyexists
to show that treating patients aged .65 years with stage 3A
CKD without albuminuria or other signs of CKD is useful,
cost-effective, or even safe. Indeed, renin-angiotensin system
(RAS) inhibitors are undoubtedly the most effective thera-
pies in nephrology to prevent ESRD. However, a recent sim-
ulation studywith real-life data demonstrated that therapies
with RAS inhibition would be considered totally ineffective
if studies were performed in elderly patients with stage 3A
CKDand no albuminuria (23). Our interpretation is that these
elderly individuals with decreased GFR are actually not CKD
patients. In this context, it must be underlined that the unique
and absolute threshold of 60 ml/min per 1.73 m2 for eGFR-
basedCKDclassiﬁcation is also questionable inyoungpeople,
especially if data on albuminuria are lacking. A patient aged
20 years with an eGFR of 65 ml/min per 1.73 m2 is certainly a
candidate forCKDdiagnosis andwill have a high lifetime risk
of later stages of CKD and of treated ESRD (24). These young
people, often with very speciﬁc nephrologic diseases like GN,
are much less common than elderly patients with CKD; how-
ever, there is a need to also focus on this group because inter-
ventions to prevent progression may be more effective. In
addition,onecannot extrapolate the results of Inker et al. toother
ancestral populations such as African Americans or Asians.
In conclusion, the data and analysis of Inker et al. are novel
and of great interest, particularly because studies of such
long duration are few and far between. This study is also a
good illustration of the effect of a given arbitrary deﬁnition
on the epidemiology of CKD. Every deﬁnition using cutoffs
or thresholds (including an age-calibrated deﬁnition) is an
arbitrary choice at worst or a fair trade-off at best. This is
especially the case for GFR, which physiologically declines
with aging. The best scientiﬁc tool to deﬁne normality for
such a “moving” parameter would be the use of percentiles,
like pediatricians use every day for height and weight. Us-
ing such normograms available in the literature (11–14)
would avoid both false negative (in young people) and false
positive (in elderly individuals) diagnoses of CKD. Because
this strategy might be considered too complex or cumber-
some for daily practice, the use of a speciﬁc threshold is
favored; however, an age-calibrated threshold seems like
good trade-off that is balanced between the two extremes
(percentiles on one side and a unique threshold on the other
side). In summary, we suggest that the lifetime risk of CKD
is much less than Inker et al. allege, largely because the def-
initions of CKD utilized by Inker et al. can be challenged
even though they substantially conform to existing guide-
lines (2). The lack of an age calibration of eGFR thresholds
for deﬁning CKD plausibly results in an inﬂation of the cu-
mulative incidence of CKD as populations and individuals
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See related article, “Lifetime Risk of Stage 3–5 CKD in
a Community-Based Sample in Iceland,” on pages 1575–1584.
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